• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雌激素受体β激动剂对卵巢癌细胞增殖和基因表达的影响。

Effect of estrogen receptor β agonists on proliferation and gene expression of ovarian cancer cells.

机构信息

Department of Obstetrics and Gynecology, University Medical Center Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany.

Center of Excellence for Fluorescent Bioanalytics (KFB), Am BioPark 9, 93053, Regensburg, Germany.

出版信息

BMC Cancer. 2017 May 8;17(1):319. doi: 10.1186/s12885-017-3246-0.

DOI:10.1186/s12885-017-3246-0
PMID:28482871
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5422944/
Abstract

BACKGROUND

Estrogen receptor (ER) β has been suggested to affect ovarian carcinogenesis. We examined the effects of four ERβ agonists on proliferation and gene expression of two ovarian cancer cell lines.

METHODS

OVCAR-3 and OAW-42 ovarian cancer cells were treated with the ERβ agonists ERB-041, WAY200070, Liquiritigenin and 3β-Adiol and cell growth was measured by means of the Cell Titer Blue Assay (Promega). ERβ expression was knocked down by transfection with specific siRNA. Additionally, transcriptome analyses were performed by means of Affymetrix GeneChip arrays. To confirm the results of DNA microarray analysis, Western blot experiments were performed.

RESULTS

All ERβ agonists tested significantly decreased proliferation of OVCAR-3 and OAW-42 cells at a concentration of 10 nM. Maximum antiproliferative effects were induced by flavonoid Liquiritigenin, which inhibited growth of OVCAR-3 cells by 31.2% after 5 days of treatment, and ERB-041 suppressing proliferation of the same cell line by 29.1%. In OAW-42 cells, maximum effects were observed after treatment with the ERβ agonist WAY200070, inhibiting cell growth by 26.8%, whereas ERB-041 decreased proliferation by 24.4%. In turn, knockdown of ERβ with specific siRNA increased cell growth of OAW-42 cells about 1.9-fold. Transcriptome analyses revealed a set of genes regulated by ERβ agonists including ND6, LCN1 and PTCH2, providing possible molecular mechanisms underlying the observed antiproliferative effects.

CONCLUSION

In conclusion, the observed growth-inhibitory effects of all ERβ agonists on ovarian cancer cell lines in vitro encourage further studies to test their possible use in the clinical setting.

摘要

背景

雌激素受体(ER)β被认为会影响卵巢癌的发生。我们研究了四种 ERβ 激动剂对两种卵巢癌细胞系增殖和基因表达的影响。

方法

用 ERβ 激动剂 ERB-041、WAY200070、甘草查尔酮和 3β-二醇处理 OVCAR-3 和 OAW-42 卵巢癌细胞,并通过 Cell Titer Blue 测定法(Promega)测量细胞生长。通过转染特异性 siRNA 敲低 ERβ 表达。此外,通过 Affymetrix GeneChip 阵列进行转录组分析。为了验证 DNA 微阵列分析的结果,进行了 Western blot 实验。

结果

测试的所有 ERβ 激动剂在 10 nM 浓度下均显著降低 OVCAR-3 和 OAW-42 细胞的增殖。黄酮类甘草查尔酮诱导最大的抗增殖作用,在 5 天的治疗后,OVCAR-3 细胞的生长抑制率为 31.2%,而 ERB-041 抑制同一细胞系的增殖率为 29.1%。在 OAW-42 细胞中,用 ERβ 激动剂 WAY200070 治疗观察到最大作用,抑制细胞生长 26.8%,而 ERB-041 使增殖减少 24.4%。相反,用特异性 siRNA 敲低 ERβ 使 OAW-42 细胞的生长增加约 1.9 倍。转录组分析揭示了一组受 ERβ 激动剂调节的基因,包括 ND6、LCN1 和 PTCH2,为观察到的抗增殖作用提供了可能的分子机制。

结论

总之,所有 ERβ 激动剂在体外对卵巢癌细胞系的生长抑制作用鼓励进一步研究以测试它们在临床环境中的可能用途。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d381/5422944/903635ebdeb2/12885_2017_3246_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d381/5422944/e69af4d939a6/12885_2017_3246_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d381/5422944/c9dfc1a59650/12885_2017_3246_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d381/5422944/46c68a0d7aaa/12885_2017_3246_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d381/5422944/f2f82089c60b/12885_2017_3246_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d381/5422944/903635ebdeb2/12885_2017_3246_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d381/5422944/e69af4d939a6/12885_2017_3246_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d381/5422944/c9dfc1a59650/12885_2017_3246_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d381/5422944/46c68a0d7aaa/12885_2017_3246_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d381/5422944/f2f82089c60b/12885_2017_3246_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d381/5422944/903635ebdeb2/12885_2017_3246_Fig5_HTML.jpg

相似文献

1
Effect of estrogen receptor β agonists on proliferation and gene expression of ovarian cancer cells.雌激素受体β激动剂对卵巢癌细胞增殖和基因表达的影响。
BMC Cancer. 2017 May 8;17(1):319. doi: 10.1186/s12885-017-3246-0.
2
Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro.雌激素受体β的激动剂及敲低对三阴性乳腺癌细胞体外侵袭能力有不同影响。
BMC Cancer. 2016 Dec 21;16(1):951. doi: 10.1186/s12885-016-2973-y.
3
Estrogen receptor β agonists affect growth and gene expression of human breast cancer cell lines.雌激素受体 β 激动剂影响人乳腺癌细胞系的生长和基因表达。
Steroids. 2013 Feb;78(2):195-202. doi: 10.1016/j.steroids.2012.10.014. Epub 2012 Nov 12.
4
Effects of a combined treatment with tamoxifen and estrogen receptor β agonists on human breast cancer cell lines.他莫昔芬与雌激素受体β激动剂联合治疗对人乳腺癌细胞系的影响。
Arch Gynecol Obstet. 2014 Jan;289(1):163-71. doi: 10.1007/s00404-013-2977-7. Epub 2013 Aug 2.
5
Knockdown of estrogen receptor β increases proliferation and affects the transcriptome of endometrial adenocarcinoma cells.雌激素受体β的敲低增加了子宫内膜腺癌细胞的增殖并影响了其转录组。
BMC Cancer. 2019 Jul 29;19(1):745. doi: 10.1186/s12885-019-5928-2.
6
Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.天然雌激素受体β激动剂对卵巢癌的治疗效用
Oncotarget. 2017 Jul 25;8(30):50002-50014. doi: 10.18632/oncotarget.18442.
7
Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.雌激素受体β选择性激动剂可降低三阴性乳腺癌细胞的侵袭性。
Int J Oncol. 2015 Feb;46(2):878-84. doi: 10.3892/ijo.2014.2778. Epub 2014 Nov 25.
8
G protein-coupled estrogen receptor 1 (GPER-1) and agonist G-1 inhibit growth of ovarian cancer cells by activation of anti-tumoral transcriptome responses: impact of GPER-1 mRNA on survival.G蛋白偶联雌激素受体1(GPER-1)及其激动剂G-1通过激活抗肿瘤转录组反应抑制卵巢癌细胞生长:GPER-1 mRNA对生存的影响
J Cancer Res Clin Oncol. 2020 Dec;146(12):3175-3188. doi: 10.1007/s00432-020-03333-4. Epub 2020 Aug 19.
9
Estrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines.雌激素受体β激动剂对人黑色素瘤细胞系的生长有不同影响。
PLoS One. 2015 Jul 30;10(7):e0134396. doi: 10.1371/journal.pone.0134396. eCollection 2015.
10
Therapeutic significance of estrogen receptor β agonists in gliomas.雌激素受体β激动剂在神经胶质瘤中的治疗意义。
Mol Cancer Ther. 2012 May;11(5):1174-82. doi: 10.1158/1535-7163.MCT-11-0960. Epub 2012 Mar 21.

引用本文的文献

1
Progress of estrogen receptor and spliceosome in endometrial carcinoma.雌激素受体与剪接体在子宫内膜癌中的研究进展
Front Endocrinol (Lausanne). 2025 Aug 25;16:1586191. doi: 10.3389/fendo.2025.1586191. eCollection 2025.
2
Harnessing Liquiritigenin: A Flavonoid-Based Approach for the Prevention and Treatment of Cancer.利用甘草素:一种基于黄酮类化合物的癌症预防和治疗方法。
Cancers (Basel). 2025 Jul 13;17(14):2328. doi: 10.3390/cancers17142328.
3
Strain and hyaluronic acid interact to regulate ovarian cancer cell proliferation, migration, and drug resistance.

本文引用的文献

1
Estrogen receptor beta and ovarian cancer: a key to pathogenesis and response to therapy.雌激素受体β与卵巢癌:发病机制及治疗反应的关键
Arch Gynecol Obstet. 2016 Jun;293(6):1161-8. doi: 10.1007/s00404-016-4027-8. Epub 2016 Feb 10.
2
Molecular changes in endometriosis-associated ovarian clear cell carcinoma.子宫内膜异位症相关卵巢透明细胞癌的分子变化
Eur J Cancer. 2015 Sep;51(13):1831-42. doi: 10.1016/j.ejca.2015.05.011. Epub 2015 Jun 6.
3
Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies.
应变与透明质酸相互作用以调节卵巢癌细胞的增殖、迁移和耐药性。
Mechanobiol Med. 2024 Sep 2;2(4):100094. doi: 10.1016/j.mbm.2024.100094. eCollection 2024 Dec.
4
An Estrogen Receptor β Agonist with AR Antagonist Activity from a Modern Asymmetric Steroid Synthesis.一种源自现代不对称甾体合成的具有雄激素受体拮抗活性的雌激素受体β激动剂。
ACS Med Chem Lett. 2025 Mar 27;16(4):631-637. doi: 10.1021/acsmedchemlett.5c00021. eCollection 2025 Apr 10.
5
Epigenetic Modulation of Estrogen Receptor Signaling in Ovarian Cancer.卵巢癌中雌激素受体信号传导的表观遗传调控
Int J Mol Sci. 2024 Dec 28;26(1):166. doi: 10.3390/ijms26010166.
6
Sparstolonin B Reduces Estrogen-Dependent Proliferation in Cancer Cells: Possible Role of Ceramide and PI3K/AKT/mTOR Inhibition.斯巴司他宁B降低癌细胞中雌激素依赖性增殖:神经酰胺和PI3K/AKT/mTOR抑制的可能作用
Pharmaceuticals (Basel). 2024 Nov 21;17(12):1564. doi: 10.3390/ph17121564.
7
The Role of Genistein and its Derivatives in Ovarian Cancer: New Perspectives for Molecular Mechanisms and Clinical Applications.染料木黄酮及其衍生物在卵巢癌中的作用:分子机制与临床应用的新视角
Curr Med Chem. 2025;32(5):907-922. doi: 10.2174/0109298673251713231019091910.
8
MicroRNAs, long non-coding RNAs, and circular RNAs and gynecological cancers: focus on metastasis.微小RNA、长链非编码RNA和环状RNA与妇科癌症:聚焦转移
Front Oncol. 2023 Oct 3;13:1215194. doi: 10.3389/fonc.2023.1215194. eCollection 2023.
9
Estrogens, Estrogen Receptors and Tumor Microenvironment in Ovarian Cancer.雌激素、雌激素受体与卵巢癌肿瘤微环境。
Int J Mol Sci. 2023 Sep 28;24(19):14673. doi: 10.3390/ijms241914673.
10
Nuclear Estrogen Receptors in Prostate Cancer: From Genes to Function.前列腺癌中的核雌激素受体:从基因到功能
Cancers (Basel). 2023 Sep 20;15(18):4653. doi: 10.3390/cancers15184653.
更年期激素使用与卵巢癌风险:52项流行病学研究的个体参与者荟萃分析
Lancet. 2015 May 9;385(9980):1835-42. doi: 10.1016/S0140-6736(14)61687-1. Epub 2015 Feb 13.
4
Cancer statistics, 2015.癌症统计数据,2015 年。
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
5
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.卵巢癌细胞系面板(OCCP):体外形态学亚型的临床重要性。
PLoS One. 2014 Sep 17;9(9):e103988. doi: 10.1371/journal.pone.0103988. eCollection 2014.
6
Recurrent epithelial ovarian cancer and hormone therapy.复发性上皮性卵巢癌与激素治疗
World J Clin Cases. 2013 Sep 16;1(6):187-90. doi: 10.12998/wjcc.v1.i6.187.
7
Effects of a combined treatment with tamoxifen and estrogen receptor β agonists on human breast cancer cell lines.他莫昔芬与雌激素受体β激动剂联合治疗对人乳腺癌细胞系的影响。
Arch Gynecol Obstet. 2014 Jan;289(1):163-71. doi: 10.1007/s00404-013-2977-7. Epub 2013 Aug 2.
8
Negative regulation of estrogen signaling by ERβ and RIP140 in ovarian cancer cells.雌激素受体β(ERβ)和受体相互作用蛋白140(RIP140)对卵巢癌细胞中雌激素信号的负调控
Mol Endocrinol. 2013 Sep;27(9):1429-41. doi: 10.1210/me.2012-1351. Epub 2013 Jul 24.
9
Frameshift mutation in the PTCH2 gene can cause nevoid basal cell carcinoma syndrome.PTCH2 基因的移码突变可导致结节性基底细胞癌综合征。
Fam Cancer. 2013 Dec;12(4):611-4. doi: 10.1007/s10689-013-9623-1.
10
p53 mutations in cancer.癌症中的 p53 突变。
Nat Cell Biol. 2013 Jan;15(1):2-8. doi: 10.1038/ncb2641.